Establishing bioequivalence of veterinary premixes (Type A medicated articles)

Authors:
Publisher website
Google Scholar
Abstract
Hunter, R. P., Lees, P., Concordet, D., Toutain, P.‐L. Establishing bioequivalence of veterinary premixes (Type A medicated articles). J. vet. Pharmacol. Therap.35 (Suppl. 1), 53–63. a) Key issues concerning Premix (Type A medicated articles) Bioequivalence evaluations: 1) This is a complex issue concerning both route of administration and formulation. 2) If the animal is not at the bunk/trough, the animal is not self‐administering (eating medicated feed), thus there can be no drug absorption. b) Differing opinions among scientists and regulatory authorities/expert bodies regarding: 1) No harmonization on how to design, conduct, and interpret in vivo studies. 2) Applicability of biowaivers to Type A (premix) products. 3) Why are topdress and complete feed considered differently? Are they different formulations or different routes of administration? 4) Single dose vs. multi‐dose studies. 5) What is the final formulation? c) What are the next steps: 1) Harmonize current bioequivalence guidelines through the VICH process. 2) Determine the applicability/non‐applicability of the Biopharmaceutical Classification System (BCS). 3) Establish the Total Mixed Ration (i.e. formulation) effects. 4) Define the test subject (individual, pen, etc.).

This publication has 27 references indexed in Scilit: